Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089524 | 0.94 | HSD17B10 (0.34) | HSD17B10MEN1KMT2ACYP2C9IMPDH2 | |
| SCHEMBL12451104 | 0.92 | HSD17B10 (0.41) | HSD17B10MEN1KMT2ACYP2C9IMPDH2 | |
| SCHEMBL20197841 | 0.91 | IMPDH2 (0.36) | HSD17B10MEN1KMT2ACYP2C9IMPDH2 | |
| SCHEMBL16071629 | 0.88 | HSD17B10 (0.32) | HSD17B10MEN1KMT2ACYP2C9IMPDH2 | |
| SCHEMBL3763099 | 0.87 | HSD17B10 (0.41) | HSD17B10MEN1KMT2ACYP2C9CYP1A2 | |
| SCHEMBL5347077 | 0.85 | MEN1 (0.32) | HSD17B10MEN1KMT2A | |
| SCHEMBL18879512 | 0.85 | HSD17B10 (0.38) | HSD17B10 | |
| SCHEMBL24258181 | 0.85 | IMPDH2 (0.33) | IMPDH2ACHE | |
| SCHEMBL14877470 | 0.85 | IMPDH2 (0.33) | HSD17B10IMPDH2ACHE | |
| SCHEMBL182607 | 0.83 | HSD17B10 (0.40) | HSD17B10MEN1KMT2ACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7014954-B2 | Nonaqueous electrolyte secondary battery including vinylene carbonate and an antioxidant in the electrolyte | SONY CORPORATION (JP) | 2006-03-21 | — | — | US | claimed |
| EP-0939073-B1 | Ester of 2,2-dimethyl-cyclopropanecarboxylic acid and their use as pesticides | SUMITOMO CHEMICAL CO (JP) | 2002-12-04 | — | — | EP | claimed |
| US-20020037458-A1 | Nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2002-03-28 | — | — | US | claimed |
| EP-1160905-A2 | Nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2001-12-05 | — | — | EP | claimed |
| EP-0939073-A1 | Ester of 2,2-dimethyl-cyclopropanecarboxylic acid and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-01 | — | — | EP | claimed |
| EP-0281439-B1 | ESTERS OF CYCLOPROPANECARBOXYLIC ACIDS RELATED TO PYRETHRIC ACID, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PARASITICIDES | ROUSSEL-UCLAF (FR) | 1991-06-12 | — | — | EP | claimed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2022204536-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-3532458-B1 | BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-01-20 | — | — | EP | disclosed |
| US-20190241521-A1 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3331860-B1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-20180170934-A1 | FOLATE DERIVATIVES, USEFUL IN PARTICULAR IN THE CONTEXT OF THE FOLATE ASSAY | bioMérieux (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180134656-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2018-05-17 | — | — | US | disclosed |
| CN-1090390-C | Non-aqueous electrolyte secondary battery | SONY CORP (JP) | 2002-09-04 | — | — | CN | disclosed |
| US-20020037458-A1 | Nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2002-03-28 | — | — | US | disclosed |
| CN-1326237-A | Nonaqueous electrolyte secondary battery | SONY CORP (JP) | 2001-12-12 | — | — | CN | disclosed |
| EP-1160905-A2 | Nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-0746050-B1 | Non-aqueous electrolyte secondary battery | SONY CORP (JP) | 1999-08-11 | — | — | EP | disclosed |
| CN-1147704-A | Non-aqueous electrolyte secondary battery | SONY CORP (JP) | 1997-04-16 | — | — | CN | disclosed |
| EP-0746050-A1 | Non-aqueous electrolyte secondary battery | SONY CORPORATION (JP) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241521-A1 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR52 | HSD17B10 725/4885MEN1 3135/4885KMT2A 3283/4885 |
| US-20180134656-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | CALR, CALD1, CYCS | HSD17B10 442/4885MEN1 3898/4885KMT2A 4788/4885 |
| US-20180170934-A1 | FOLATE DERIVATIVES, USEFUL IN PARTICULAR IN THE CONTEXT OF THE FOLATE ASSAY | FOLR2, FOLR1, DHFR | HSD17B10 859/4885MEN1 1944/4885KMT2A 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.